ScholarLens Back to search
2007•Shanxi Yike Daxue xuebaoRequires access

Expression of CD19, CD56 and CD2 in acute myeloid leukemia

Zhu Lei

Open publisher page 0 citations

Abstract

Objective To study the expression of CD19, CD56 and CD2 in acute myeloid leukemia and their significance in detecting minimal residual disease(MRD). Methods One hundred and thirty bone marrow specimens of new AML patients were selected,and immunophenotypes were assayed using three sets of 4-color antibodies combination(CD34/CD13/CD45/CD19, CD34/CD56/CD33/CD45 and CD34/CD2/CD33/CD45)by multiparameter flow cytometry(MFC). Results Expression frenquence of CD19 was 2.31%, CD56 was 3.75%, and CD2 was 1.25% in AML.None of them were detected in M3. Conclusion Expression frenquence of CD19, CD56, CD2 in AML is low. CD56, CD2 may be markers in detecting MRD in AML, but CD19 could be not.

About this research paper

What this paper is about

Objective To study the expression of CD19, CD56 and CD2 in acute myeloid leukemia and their significance in detecting minimal residual disease(MRD). Methods One hundred and thirty bone marrow specimens of new AML patients were selected,and immunophenotypes were assayed using three sets of 4-color antibodies combination(CD34/CD13/CD45/CD19, CD34/CD56/CD33/CD45 and CD34/CD2/CD33/CD45)by multiparameter flow cytometry(MFC). Results Expression frenquence of CD19 was 2.31%, CD56 was 3.75%, and CD2 was 1.25% in AML.None of them were detected in M3. Conclusion Expression frenquence of CD19, CD56, CD2 in AML is low. CD56, CD2 may be markers in detecting MRD in AML, but CD19 could be not.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To study the expression of CD19, CD56 and CD2 in acute myeloid leukemia and their significance in detecting minimal residual disease(MRD). Methods One hundred and thirty bone marrow specimens of new AML patients were selected,and immunophenotypes were assayed using three sets of 4-color antibodies combination(CD34/CD13/CD45/CD19, CD34/CD56/CD33/CD45 and CD34/CD2/CD33/CD45)by multiparameter flow cytometry(MFC). Results Expression frenquence of CD19 was 2.31%, CD56 was 3.75%, and CD2 was 1.25% in AML.None of them were detected in M3. Conclusion Expression frenquence of CD19, CD56, CD2 in AML is low. CD56, CD2 may be markers in detecting MRD in AML, but CD19 could be not.

Key concepts: CD33, CD34, Myeloid leukemia, CD19, Minimal residual disease, Flow cytometry, Medicine, Immunophenotyping

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Expression of CD19, CD56 and CD2 in acute myeloid leukemia — Research Paper | ScholarLens